Clinical trials
Prostate clinical trials
Below are recruiting prostate clinical trials, each written for real people, not researchers. We’re tracking 1,366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07198633RecruitingPhase 1/Phase 2
Study of new drugs for advanced prostate cancer
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06321679Recruiting
Study of bone scans for advanced prostate cancer treatment
This trial is testing how well treatments for advanced prostate cancer that has spread to the bones can be seen on scans. It may help doctors find better ways to measure if the cancer is responding to treatment.
MilanAges 18 years+ - NCT07289243Recruiting
Comparing laser therapy and standard surgery for an enlarged prostate
This trial compares a new laser treatment (Echolaser SORACTELITE-TPLA) with the standard surgery (TURP) for men with bothersome urinary symptoms caused by an enlarged prostate. The goal is to see which approach works better at reducing symptoms like needing to urinate frequently or urgently.
Bari, ITALY/BariAges 40–85 - NCT05646550RecruitingPhase 1
Antibody CC-1 for men with returning prostate cancer
This Phase 1 study tests an antibody drug (CC-1) for men whose prostate cancer has come back, based on rising PSA blood tests. It looks at safety and how the treatment affects cancer activity, especially whether it can help control early biochemical recurrence.
TübingenAges 18 years+ - NCT06273345Recruiting
Treating the primary tumor for prostate cancer that has spread a little
This trial studies whether treating the main prostate tumor with local therapy (like surgery or radiation) along with hormone therapy is beneficial for men whose cancer has spread to only a few spots in the body (low-volume metastases). It focuses on men who have not had any prior treatment for their prostate cancer.
Brixen, BolzanoAges 18 years+ - NCT06828263Recruiting
Imaging markers during PSMA therapy for prostate cancer
This trial is testing a new imaging approach during treatment with a radioactive drug (Lu-PSMA) for men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if imaging changes can help predict how well the treatment is working.
GrenobleAges 18 years+ - NCT06803602Enrolling by invitation
Magnetic therapy for urine leaks after prostate surgery
This trial tests a non-invasive magnetic treatment (HIFEM) to help men with urine leaks after prostate cancer removal (radical prostatectomy) or HoLEP surgery. The goal is to see if it improves bladder control and quality of life.
Scottsdale, ArizonaAges 18–100 - NCT06949254Recruiting
Study of radiation and hormone therapy for high-risk prostate cancer
This study looks at combining stereotactic body radiation therapy (a precise type of radiation) with hormone therapy for men with high-risk prostate cancer that hasn't spread. The goal is to see how well this treatment works with fewer side effects.
Bergamo, BergamoAges 18 years+ - NCT06001255RecruitingPhase 2
Testing HS-20093 for advanced prostate and other solid cancers
This trial is testing a new drug called HS-20093 for people with advanced prostate cancer or other solid tumors that have spread and stopped responding to standard treatments. The drug targets a protein on cancer cells to try to stop cancer growth.
BeijingAges 18 years+ - NCT06491108RecruitingPhase 3
Medication for moderate prostate symptoms in sexually active men
This study tests whether a medication can help men with moderate urinary symptoms from an enlarged prostate. It's for men who are already on prostate medicine and have been closely monitored for 12 weeks.
Tanta, Gharbia GovernorateAges 40–70 - NCT06380738Recruiting
Real-world study of olaparib plus abiraterone for advanced prostate cancer
This trial is for people with advanced prostate cancer (mCRPC) who are already taking the combination of olaparib and abiraterone. It will look at how these two medicines work together in real-world practice.
AschaffenburgAges 18 years+ - NCT06343038RecruitingPhase 1
A new targeted radiation drug for advanced prostate cancer
This trial tests a new radioactive drug (161Tb-SibuDAB) for men with metastatic prostate cancer that has grown despite standard treatments. It aims to find the right dose and see if it can shrink tumors.
BaselAges 18 years+ - NCT06335914Recruiting
Dual PET scans for advanced prostate cancer
This study tests whether two kinds of PET scans, one targeting PSMA and one targeting sugar uptake (FDG), can help doctors better understand advanced prostate cancer. If you have prostate cancer that has spread (metastatic) and still responds to hormone therapy, the scans may help guide your treatment.
Toronto, OntarioAges 18 years+ - NCT06325995Recruiting
Short radiation course after prostate surgery for rising PSA
This trial tests a shorter, stronger course of radiation (hypofractionated radiotherapy) given after prostate removal surgery. It may help people whose PSA levels rise again after surgery, aiming to reduce side effects and improve outcomes.
Shanghai, Shanghai MunicipalityAges Any age - NCT06242509Recruiting
Akkermansia bacteria in prostate cancer
This trial looks at whether a specific gut bacterium, Akkermansia muciniphila, is linked to how well hormone therapy works in men with advanced prostate cancer that no longer responds to standard hormone treatment. You may join if you are about to start a new type of hormone therapy.
ParisAges 18–100 - NCT06204341Recruiting
Finding the best radiation for high-risk prostate cancer
This trial compares different radiation therapy plans for men with high-risk prostate cancer that has spread to the lymph nodes. It aims to find the best way to treat the prostate and the surrounding lymph nodes while minimizing side effects.
Leidschendam, South HollandAges 18 years+ - NCT07311694RecruitingPhase 3
Comparing a new treatment with standard drugs for advanced prostate cancer
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06568562RecruitingPhase 2
XL092 for advanced prostate cancer after PSMA therapy
This trial tests a new oral drug, XL092, for men with metastatic castration-resistant prostate cancer that has progressed after PSMA-targeted radiation therapy (Lu-177 PSMA-617). It aims to see if the drug can slow down the cancer.
Salt Lake City, UtahAges 18 years+ - NCT06470750Recruiting
Home care for prostate cancer in Black men
This study looks at whether giving some prostate cancer care at home can help Black men and other patients who have trouble getting to the clinic. It tests if home-based care for treatments like hormone therapy, oral pills, or chemotherapy is practical and helps reduce health care gaps.
Jacksonville, FloridaAges 18 years+ - NCT07241416RecruitingPhase 3
Rezvilutamide for metastatic hormone-sensitive prostate cancer
This trial tests a new drug, rezvilutamide, combined with standard hormone therapy for men with prostate cancer that has spread but still responds to hormone treatment. The goal is to see if this drug helps control the cancer longer than the usual treatment alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07164443RecruitingPhase 3
Study comparing pasritamig to placebo for advanced prostate cancer
This trial tests a new drug called pasritamig against a placebo for people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. The goal is to see if pasritamig can help slow the cancer's growth.
La Jolla, CaliforniaAges 18 years+ - NCT07164456Recruiting
Family support program for Black prostate cancer survivors
This study tests a family-based program to help Black prostate cancer survivors and their caregivers live healthier. You and a family member will join together to improve diet, activity, and well-being.
Houston, TexasAges 18 years+ - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Goodyear, ArizonaAges 18 years+ - NCT07364071RecruitingPhase 2
Hormone therapy and targeted radiation for high-risk prostate cancer
This trial tests whether combining standard hormone therapy and radiation with a special targeted radiation (PSMA-targeted radiotherapy) is safe and effective for men with high-risk prostate cancer that hasn't spread outside the pelvis.
La Jolla, CaliforniaAges 18 years+
Hear when a new Prostate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate?
- Yes. Clin2 currently lists 1,366 recruiting prostate studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.